The Japan Times - Once-taboo ketamine booms for US at-home mental care

EUR -
AED 3.80597
AFN 78.367435
ALL 99.666738
AMD 414.886421
ANG 1.869939
AOA 472.514437
ARS 1090.728201
AUD 1.67484
AWG 1.867779
AZN 1.758731
BAM 1.955736
BBD 2.094931
BDT 126.525859
BGN 1.955736
BHD 0.391187
BIF 3071.19948
BMD 1.036216
BND 1.408054
BOB 7.169765
BRL 6.053537
BSD 1.037566
BTN 89.82806
BWP 14.451527
BYN 3.395489
BYR 20309.835263
BZD 2.084132
CAD 1.520643
CDF 2956.3242
CHF 0.944371
CLF 0.037078
CLP 1023.106514
CNY 7.447077
CNH 7.611157
COP 4309.558949
CRC 523.38287
CUC 1.036216
CUP 27.459726
CVE 110.261391
CZK 25.198858
DJF 184.763953
DKK 7.462796
DOP 64.097902
DZD 140.180412
EGP 52.046297
ERN 15.543241
ETB 132.90715
FJD 2.407078
FKP 0.853414
GBP 0.836177
GEL 2.963526
GGP 0.853414
GHS 15.87448
GIP 0.853414
GMD 75.126075
GNF 8968.706456
GTQ 8.025737
GYD 217.072895
HKD 8.075802
HNL 26.431135
HRK 7.646806
HTG 135.715558
HUF 410.403933
IDR 16947.573122
ILS 3.711617
IMP 0.853414
INR 89.696417
IQD 1359.155515
IRR 43624.69708
ISK 146.686282
JEP 0.853414
JMD 163.634644
JOD 0.734885
JPY 160.64044
KES 133.845619
KGS 90.617169
KHR 4174.863358
KMF 489.974689
KPW 932.594592
KRW 1510.575296
KWD 0.319652
KYD 0.864672
KZT 537.642403
LAK 22573.261182
LBP 92912.958979
LKR 309.19988
LRD 206.473242
LSL 19.366666
LTL 3.059677
LVL 0.626797
LYD 5.093833
MAD 10.414759
MDL 19.371366
MGA 4824.842084
MKD 61.527986
MMK 3365.589423
MNT 3521.062368
MOP 8.328627
MRU 41.56464
MUR 48.339561
MVR 15.967932
MWK 1799.141114
MXN 21.743746
MYR 4.616325
MZN 66.224362
NAD 19.366666
NGN 1557.43294
NIO 38.17875
NOK 11.736743
NPR 143.725296
NZD 1.846232
OMR 0.398917
PAB 1.037566
PEN 3.859774
PGK 4.224862
PHP 60.536789
PKR 289.399628
PLN 4.242227
PYG 8183.732148
QAR 3.782076
RON 4.960066
RSD 117.126166
RUB 102.196655
RWF 1472.751797
SAR 3.886533
SBD 8.759849
SCR 14.861514
SDG 622.766103
SEK 11.581601
SGD 1.408017
SHP 0.853414
SLE 23.703442
SLL 21728.933109
SOS 592.980592
SRD 36.370664
STD 21447.580845
SVC 9.078703
SYP 13472.88152
SZL 19.354367
THB 34.847696
TJS 11.345629
TMT 3.637118
TND 3.313892
TOP 2.426925
TRY 37.13669
TTD 7.03777
TWD 34.13817
TZS 2645.713406
UAH 43.270984
UGX 3819.874976
USD 1.036216
UYU 44.89853
UZS 13462.559373
VES 60.484555
VND 25988.299409
VUV 123.021654
WST 2.902262
XAF 655.935531
XAG 0.0331
XAU 0.00037
XCD 2.800426
XDR 0.793174
XOF 655.935531
XPF 119.331742
YER 257.888254
ZAR 19.42272
ZMK 9327.187522
ZMW 29.02605
ZWL 333.661157
  • CMSD

    -0.3800

    23.84

    -1.59%

  • CMSC

    -0.2100

    23.47

    -0.89%

  • NGG

    -0.3400

    61.4

    -0.55%

  • SCS

    -0.1600

    11.48

    -1.39%

  • AZN

    -0.4800

    70.76

    -0.68%

  • RIO

    -0.5000

    60.41

    -0.83%

  • RELX

    -0.4600

    49.89

    -0.92%

  • GSK

    -0.0900

    35.27

    -0.26%

  • RYCEF

    -0.0600

    7.43

    -0.81%

  • RBGPF

    67.2700

    67.27

    +100%

  • VOD

    -0.0700

    8.54

    -0.82%

  • BCC

    -2.5000

    126.16

    -1.98%

  • BP

    -0.5500

    31.06

    -1.77%

  • BCE

    -0.1100

    23.79

    -0.46%

  • BTI

    -0.0400

    39.64

    -0.1%

  • JRI

    -0.0400

    12.53

    -0.32%

Once-taboo ketamine booms for US at-home mental care
Once-taboo ketamine booms for US at-home mental care

Once-taboo ketamine booms for US at-home mental care

Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.

Text size:

A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.

Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.

"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."

Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.

It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.

In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.

- Ketamine 'babysitter' -

Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.

An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.

Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.

"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.

For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.

Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.

"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.

Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.

- 'Change your life' -

US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.

Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.

He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.

"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.

Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.

Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.

Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.

"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.

M.Yamazaki--JT